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Emmons, Tiffany, M.S. Summer 2014 Biology 
The Effects of Estrogen in Atrazine-mediated Foxp3 Induction and Inhibition of 
CD4+ T effector Cells 
Atrazine (ATR) is a chlorotriazine herbicide that is heavily used in agricultural 
areas. Atrazine was banned in Europe in 2006 but it is still used in the United States. It 
is also the most common drinking water contaminant in the United States. Atrazine has 
been linked to adverse health effects and displays immunotoxicity. It is a potent 
phosphodiesterase inhibitor and has been shown to induce aromatase activity leading 
to elevated estrogen levels. Previous studies demonstrated that in vitro atrazine 
exposure inhibits CD4+ T cell activation and proliferation and increases the frequency of 
Foxp3+ CD4+ T cells with more severe phenotypes in male-derived cells. The decreased 
proliferation and activation of CD4+ T cells was not replicable by pharmacologically 
increasing cAMP. This, along with the sex bias, suggested that ATR elevation of 
estrogen could mediate an increased severity in T cell proliferation and activation, 
specifically through GPER-1. We show that treatment with the GPER-1 agonist G-1 can 
mimic effects seen with low concentrations of ATR but blockade of GPER-1 with the 
antagonist G-36 does not alleviate ATR-mediated effects on CD4+ T cells. We also 
show that estrogen can synergize with ATR to further decrease CD4+ T cell proliferation 
and activation upon challenge with antigen. Overall, GPER-1 does not appear to be 
involved in the ATR mediated decrease in CD4+ T cell proliferation, activation, or 
increase in the frequency of Foxp3+ Tregs in vitro.  
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1 
Introduction 
Atrazine Exposure and 
Regulations 
Atrazine (ATR) is a chlorotriazine 
herbicide that kills broadleaf and grassy 
weeds by inhibiting photosynthesis (1). It 
inhibits electron transport by blocking 
electron flow from plastoquinone A to QB in 
photosystem II (2). It is estimated that 76.4 million 
pounds are applied annually on corn, sorghum and 
sugarcane crops in the United States (U.S.) (1). The 
large-scale use of this herbicide makes it the most 
common contaminant of ground and drinking water with more than half of the U.S 
population exposed (3). Atrazine is sprayed onto crops allowing for the wind to spread 
droplets to areas outside of the application site. Water run-off also spreads atrazine into 
aquifers and near-by streams allowing for a larger area of contamination and 
contamination of drinking water. About 75% of stream samples (40% containing more 
than 0.1ppb ATR) and 40% of groundwater samples (more than 10% containing more 
than 0.1ppb ATR) in agricultural areas of the U.S. contained ATR between 1992 and 
2001 with slight elevations seen in more recent years (4). 
The U.S. maximum containment level (MCL), which is the highest concentration 
allowed in drinking water, of atrazine is 3 parts per billion (ppb) (5). Since ATR is not 
classified as a carcinogen (6), the MCL is determined by taking the safe dose (the 
Figure 1: 2007 estimates of 
maximum 21-day average Atrazine 
concentrations in streams. The colors 
on the map refer to the concentration of 
Atrazine found (blue=lowest, 
orange=highest). Higher concentrations 
of Atrazine are found in streams near 
where Atrazine is most heavily used. 
Provided by the USGS.  
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lowest dose thought to not cause adverse effects) and dividing it by five. The division by 
five is done to account for other modes of exposure such as from food, air or skin 
absorption (7,8)., MCLs are based on yearly averages, which can allow for huge 
concentration spikes over the MCL during the spraying season. It is estimated that over 
200,000 people are exposed to levels above the MCL (9). The No-observed-adverse-
effect-level (NOAEL) is 10mg/kg/day while the Lowest-observed-adverse-effect-level 
(LOAEL) is 70/mg/kg/day) (9). In spite of potential health effects, atrazine regulation has 
become a very controversial topic because it is cheap and effective. The European 
Union (EU) banned its use in 2006 because of potential health effects and the inability 
to reduce water contamination below 0.1ppb (which they required because they do not 
recognize a safe level in drinking water) (4, 26).  
Even with regulations set in place, the concentration of ATR in bodies of water 
and rain vary drastically. Levels as high as 4,000 ppb have been reported in runoff from 
treated fields and 2.5ppb in rainfall around agricultural and non-agricultural areas (10). 
Even though the use of atrazine is regulated, one of the main concerns lies with those 
that actually apply it to crops. Atrazine applicators are at risk of directly exposing 
themselves and their families to hazardous levels of atrazine. ATR has been found to 
contaminate dust and air within farming homes leading to increased levels of atrazine 
and its metabolites in urine. A significant level of atrazine in urine is also found in non-
farming families because atrazine is easily spread from the initial application site (11).  
Biochemical activities of Atrazine 
Atrazine is known as an endocrine disrupting compound (EDC) because it can 
alter testosterone and estrogen levels. Atrazine can induce expression of aromatase, 
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which converts androgens to estrogens, and ultimately increases estrogen levels (12). 
ATR has also been shown to interfere with testosterone synthesis that ultimately causes 
a decrease in serum and plasma levels of testosterone (13).  
Due to ATR’s endocrine disrupting activity, its effects can vary depending on the 
concentrations used. Traditional, monotonic, dose-response curves have a defined 
relationship between the dose and the biological effect as seen in Figure 2. However, 
EDCs have been shown to exhibit non-monotonic dose responses, meaning that the 
relationship between dose and effect is not linear (14). This means that in some 
instances lower doses of EDCs may have more severe effects than higher doses, as 
displayed in Figure 2 (15). 
 
 
Along with ATR’s endocrine disrupting function, it is also known to be a very 
potent cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) inhibitor 
(16). Phosphodiesterase inhibition leads to an increase of intracellular cAMP, which has 
also been linked to aromatase induction (17). ATR is a more potent PDE inhibitor than 
the well-characterized, non-selective PDE inhibitor isobutyl methylxanthine (IBMX). 
While IBMX displayed significant PDE inhibition down to 500nM, ATR was active down 
to 5nM demonstrating a 100-fold increase in potency versus IBMX (17).  
Figure 2: Monotonic versus Non-monotonic dose curves. Adapted 
from (15). 
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The increase of intracellular cAMP has many different biological effects. In CD4+ 
T lymphocytes elevated cAMP stabilizes the transcription of forkhead box protein 3 
(Foxp3). Foxp3 is the master transcriptional regulator of regulatory T cells (Tregs). Within 
the first intron of Foxp3 is a CpG island that, if unmethylated, is bound by cAMP 
response element binding protein (CREB), which maintains Foxp3 expression. About 
45% of naïve CD4+ T cells have methylated CpG regions within the Foxp3 gene 
whereas CD4+ CD25+ regulatory cells displayed no methylation (18). The demethylated 
region in naïve cells could potentially give rise to Foxp3 expressing Treg cells if they 
experienced an increase in intracellular cAMP. 
Atrazine Metabolism 
There are twelve known metabolites of atrazine with the most common being 
desethyl atrazine (DE), desisopropyl atrazine (DIP) and diaminochlorotriazine (DACT) 
(19). Atrazine is not known to bioaccumulate (20, 21) and its half life in the environment 
varies depending on whether it is in water, soil or the body. The half life of atrazine in 
soil is 146 days and 742 days in water (4, 22). A study done by Ross et al. looked at the 
concentration of atrazine and its metabolites in urine, plasma, and various body tissues 
of mice. Mice were administered one dose of atrazine, ranging from 5mg/kg to 
250mg/kg, via oral gavage. Mice exposed to the highest level of atrazine had detectable 
levels of atrazine and its metabolites in their plasma and urine for 48 to 72 hours. DACT 
was found at higher levels (50µM in urine) than all other metabolites and lasted the 
longest in the body (up to 96 hours). ATR levels peaked 1 hour after exposure and were 
found at 28µM in urine and 11µM in the spleen and thymus after 4 hours. ATR levels 
declined between 24 and 48 hours (19). Although the highest dose (250mg/kg) is higher 
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than the LOAEL (70mg/kg/day), the study only looked at short-term atrazine exposure. 
It is currently unclear what the levels of ATR and its metabolites in plasma, urine, or 
body tissue during chronic exposure to lower levels of ATR. Such experiments would 
better mimic human exposure patterns. 
The adverse effects of ATR metabolites have not been studied extensively. The 
main metabolite, DACT, has been shown to decrease levels of testosterone more 
severely than treatment with ATR (13). Treatment with 100mg/kg or 200mg/kg of DACT 
or ATR decreased transcription levels of proteins associated with testosterone synthesis 
in the testis of male mice. DACT reduced transcript levels more severely than ATR but 
that could be due to the breakdown of ATR into many different metabolites versus pure 
levels of DACT. DACT suppresses luteinizing hormone (LH) release in mice (23). LH 
triggers ovulation in females and testosterone production in males. A reduction of LH 
can delay puberty in both sexes, which can be confirmed as a side-effect of ATR 
treatment or ATR metabolite treatment in male and female rats (24, 25)., Most of the 
metabolite effects studied have focused on changes in tissues and endocrine disruption, 
but metabolite effects on the immune system have yet to be examined. 
Environmental and Health Effects of Atrazine 
Multiple studies have linked atrazine to increases in prostate and breast cancer 
(27, 28, 29).,, Males employees working in atrazine production plants had higher 
incidences of prostate cancer (28), while breast cancer incidence correlate with atrazine 
application sites (29). In contrast to these studies, a 2011 study from Freeman et al. 
found no significant increases in cancer amongst atrazine applicators, with the 
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exception of a small increase in thyroid cancer (27). These, and other, conflicting results 
lead the IARC to conclude atrazine is “not classifiable as a human carcinogen.” 
  In addition to cancer, atrazine exposure is linked to fetal developmental 
problems such as low birth weight, fetal limb defects, and pre-term delivery (30, 31, 
32).,, A study done by Winchester et al. found a correlation between increased usage of 
atrazine between April and July and birth defects in children conceived during that time. 
Men were also found to have abnormal sperm during the same months (33). Women 
exposed to ATR during their third trimester resulted in a 17-19% increase of small-for-
gestational-age babies (low birth weight) and exposure over the entire pregnancy 
significantly increased these chances by 11% (30). Most pregnancy complications, such 
as pre-term delivery and small for gestational age, arose when the mother was pregnant 
with a boy (32, 30). The effects on male fetuses could be due to atrazine’s effect as an 
endocrine disrupting compound. 
 Atrazine in the environment has also been the focus of a lot of research. The 
most widely reported environmental concern regarding ATR is the feminization of frogs 
and fish exposed to ATR. Due to ATR’s ability to induce aromatase and increase 
estrogen, frogs grown in the presence of ATR have decreased testosterone levels and 
feminization of their gonads (production of female oocytes in testes) (34). As study done 
by Hayes et al. found that in leopard frogs exposed to 0.1ppb of atrazine, 12% of males 
had under-developed testes with low to no production of germ cells. Around 8% of frogs 
treated with 25ppb displayed sex-reversal and production of female oocytes. These 
findings were confirmed at high usage agricultural sites. For one high-usage site near 
the North Platte River in Wyoming, 92% of sampled males showed signs of sex-reversal 
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(35). Another study looking at the effect of atrazine at or above the MCL shows that 
frogs exposed to 3ppb of ATR had lower survival rates than frogs exposed to higher 
concentrations (36). Although this result appears counterintuitive, it displays ATR’s non-
monotonicity. The results of these studies show that ATR can severely alter the sex 
ratios and survival rates of amphibians in the wild. This can directly skew reproduction 
and population numbers and pose an ecological threat to frogs. 
Immunotoxicity of Atrazine 
Immunotoxic effects of atrazine have previously been observed. Treatment with 
ATR inhibits natural killer (NK) cell lytic granule release, compromising the ability to kill 
target cells. Cell-to-cell contact and concentrations of lytic proteins remained unchanged 
but the exocytosis of lytic proteins was inhibited in ATR cultures (37). Atrazine treatment 
decreased dendritic cell (DC) maturation in primary murine DC and the murine dendritic 
cell line JAWSII (38). The percentage of mature dendritic cells (defined as CDllc high) 
decreased 24 hours after treatment with 1µM ATR compared to controls. A study done 
by Filipov et al. looked at immunotoxic effects of short term ATR exposure in vivo. Male 
mice were exposed to 5, 25, 125, or 250mg/kg of ATR daily via oral gavage for 14 days 
and then analyzed at 1 day, 1 week, and seven weeks after the last ATR exposure. 
Mice treated with 125 mg/kg/day had significantly decreased thymus and spleen 
weights and thymus and spleen cellularity were reduced with concentrations as low as 
25/mg/kg/day ATR. The reduced splenic cellularity lasted up to seven weeks. Higher 
levels of ATR (125 and 250mg/kg/day) decreased the number of splenic and circulating 
naïve CD4
+
 T cells and increased the percentage of highly activated cytotoxic/memory 
T cells (39). These studies suggest that ATR is potentially immunosuppressive but 
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much remains unknown about how ATR affects adaptive immunity, specifically CD4+ T 
cells.  
T cell Functions 
CD4+ T cells are essential components in the generation of a protective adaptive 
immune response. CD4+ T cells are divided into functionally distinct effector subtypes 
based upon cytokine products and gene expression patterns. The currently well 
characterized CD4+ T cell subsets are T helper type 1 (TH1), T helper type 2 (TH2), T 
helper type 17 (TH17), T follicular helper cells (TFH) and regulatory T cells (Tregs). TH1 
CD4+ T cells are associated with cell-mediated immunity and defense against 
intracellular pathogens (40). TH1 cells are associated with delayed-type hypersensitivity 
and the production of pro-inflammatory cytokines such as interferon gamma (IFNγ) and 
tumor necrosis factor alpha (TNFα) (41). TH2 CD4
+ T cells are associated with humoral 
immunity and defense against extracellular pathogens by encouraging antibody 
production (40). TH2 responses are also associated with allergic inflammation and 
asthma (42). TH17 CD4
+ T cells help defend against parasites and are known to 
strongly influence gut-associated immunity (43). TFH cells are found in lymphoid follicles 
and function to help B cells undergo antibody class switching and somatic 
hypermutation to create higher affinity antibodies (44).  
In contrast to the previously mentioned CD4+ T cell subsets, regulatory T cells 
(Tregs) suppress immune responses in order to maintain self-tolerance. The most well 
characterized Treg population expresses the transcription factor Foxp3, and the 
interleukin 2 receptor  chain (CD25). They are defined as CD4+ CD25+ Foxp3+ Treg. 
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Foxp3 is the master transcriptional regulator of Tregs and its expression drives 
expression of a set of genes that are associated with Treg function. As mentioned above, 
Foxp3 expression can be induced via elevated cAMP. Tregs naturally have higher levels 
of cAMP and can use this to suppress effector T cells (Teff) (45). In fact, elevated cAMP 
is also an effector mechanism of Tregs as Tregs directly transfer cytoplasmic cAMP via 
gap-junctions into effector T cells (45). The subsequent increase of cAMP in effector T 
cells increases the level of inducible cAMP early repressor protein (ICER), which then 
inhibits proliferation and IL-2 synthesis resulting in decreased activation (46). Tregs can 
also mediate suppressive action through contact independent mechanisms, including 
the secretion of anti-inflammatory cytokines like IL10 and TGF (47, 48).,  
The balance of the frequency of Tregs to effector T cells is critical in maintaining 
immune homeostasis. Decreased frequencies of Tregs correlate with increases in 
autoimmune diseases, such as rheumatoid arthiritis (49) and atopic dermatitis (50), due 
to the lack of suppression. On the other hand, increased Treg frequencies can also lead 
to disease progression by inhibiting protective responses against pathogens like 
Mycobacterium tuberculosis (51). In this case, the increased number of Tregs suppresses 
the active immune response against the pathogen, preventing the pathogen from being 
cleared and allowing continued infection. Increased frequencies of Tregs can occur 
through two methods: proliferation and expansion of natural Tregs (nTregs, derived from 
the thymus) (52) or induction of effector T cell conversion into Tregs (iTregs, made outside 
of the thymus) (53). Both nTreg and iTreg populations are potent inhibitors of immune 
responses. Major disruption in the balance of Treg populations can have detrimental 
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effects on self-tolerance, pathogen clearance and can also favor the development of 
cancer (54). 
CD4+ T cell 
Subset 
Transcription 
factor 
Characteristic 
cytokine 
Characteristic function 
TH1 T-bet IFNγ Intracellular pathogens 
TH2 Gata-3 IL-4 Extracellular pathogens 
TH17 RORγt IL-17 
Extracellular bacteria, 
parasites 
TFH Bcl-6 IL-21 
Antibody class switching, B 
cell interactions 
Treg Foxp3 TGFβ 
Immune tolerance and 
regulation 
 
 
  
Table 1: CD4+ T cell subsets and functions. (55) 
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Effects of Atrazine on CD4
+
 T cells 
Previous work in the Wetzel laboratory investigated the effects of ATR on CD4+ T cells. 
Figure 3 shows that treatment with 30µM atrazine consistently reduced the number of 
CD4+ T cells in culture, with a mean reduction of 70.6%. This reduction was due to 
decreased CD4+ T cell proliferation (Figure 4). CD4+ T cells cultured in the presence of 
30µM ATR were stained with carboxyfluorescein succinimidyl ester (CFSE) to monitor 
proliferation. CFSE non-specifically labels intracellular proteins and upon division the 
fluorescence for each daughter cell is only half as bright as the parent cell. Proliferating 
cells have decreased CFSE whereas non-proliferating cells retain a high CFSE signal. 
As seen in Figure 4, 30µM ATR severely reduced proliferation compared to the 
untreated and EtOH-only cultures.  
Figure 3: Atrazine decreases the 
amount of CD4+ T cells in culture. 
The percent reduction in the absolute 
number of CD4
+
 T cells in the 30µM 
ATR-treated cultures compared to the 
EtOH-only control cultures is shown for 
6 separate experiments. Cells were 
stimulated with 2.5µM MCC peptide. 
The ATR-associated mean reduction in 
CD4
+
 T cells for these 6 experiments 
was statistically significant * p=0.0058 . 
(Thueson, et al., in revision). 
 
Figure 4: Treatment with 30µM ATR (green 
line) decreases CD4+ T cell proliferation 
compared to the untreated (pink line) and 
EtOH only controls (shaded grey). Cells were 
stimulated with 2.5µM MCC peptide. (Thueson 
et al., in revision). 
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Along with decreased proliferation, 30µM ATR exposure also decreased CD4+ T 
cell activation (Figure 5, Top row). Activation was assessed by staining CD25 and CD69 
after 4 days in culture. Expression of both CD25, the interleukin 2 receptor alpha chain 
(56), and CD69, a cell surface glycoprotein, increase upon activation (57). The 
frequency of CD25+ CD69+ cells in the EtOH culture was 77.4%, which was significantly 
higher than 13.2% of CD25+ CD69+ cells found in the ATR culture. Interestingly, the 
decreased expression of CD25 and CD69 correlated with an increase in the frequency 
of Foxp3+ regulatory T cells (Tregs) (Figure 5, Bottom row). 30µM ATR exposure typically 
increases the frequency of Foxp3 by 2-5 fold. The observed decrease in the activation 
and proliferation of the CD4+ T cells in ATR treated cultures may be due to the functions 
of increased numbers of Tregs in the cultures.  
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 As mentioned earlier, increases in cAMP can stabilize expression of Foxp3. Thus 
the rise in Foxp3 expression could be mediated through ATR’s PDE inhibitor function. In 
order to test this hypothesis, cells were treated with the PDE inhibitor pentoxyfilline 
(PTX). Upon treatment with PTX, CD4+ T cells displayed both decreased proliferation 
(data not shown) and decreased activation (Figure 6). 11.4% of CD4+ T cells treated 
with PTX were CD25+ CD69+ while 6.2% were CD25+ CD69+ in the atrazine treated 
cultures. While supportive of a role for elevated cAMP in the ATR immunotoxic effects, 
the difference between ATR and PTX suggest additional factors may be involved. 
Coincidentally it was observed that cells derived from male mice were more sensitive to 
ATR than cells derived from female mice (Figure 7). Male CD4+ T cells did not 
proliferate as well as the female CD4+ T cells upon treatment with the same 
concentration of ATR (30µM). Since ATR decreased activation more than that seen with 
Figure 5: Treatment with 30µM ATR decreases CD4+ T cell activation. Cells were stimulated with 
2.5µM MCC peptide. Activation was determined by staining CD25 and CD69. 30µM ATR has 13.2% of 
CD25+ CD69+ T cells (Top, right) while the EtOH only control has 77.4% (Top, middle). Treatment with 
30µM ATR also increased the frequency of Foxp3+ CD25+ T cells by more than 5 fold (Bottom, left) 
compared to the EtOH control (Bottom, right). (Thueson et. al., in revision) 
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a PDE inhibitor alone and male cells were more affected than female cells, it raises the 
possibility that ATR’s endocrine disrupting function could be playing a role in the effects 
on CD4+ T cell proliferation and activation.  
 
 
 
 
 
 
 
 
 
 
Estrogen as an Immunomodulator 
Since ATR can increase levels of estrogen, elevated levels of estrogen could 
potentially be causing the increased severity of ATR seen in Figure 6. Estrogen is 
known to be a very potent immunomodulator. Antigen stimulated human T cells cultured 
in the presence of estrogen (1000-1500 pg/ml) proliferate poorly compared to controls 
Figure 6: Treatment with 250 µM PTX can reduce proliferation (data not known) and 
activation of CD4+ T cells. 30µM ATR has 6.2% CD25+ CD  69+ T cells compared to 
11.4% in the presence of PTX and 82.8% in the ethanol control. (Thueson et al., in 
revision) 
Figure 7: Effects of 30 µM ATR on male 
(blue) and female (pink) CD4+ T cells. 
Male and female cells display decreased 
proliferation compared to the EtOH 
vehicle control (shaded grey), although 
male cells do not proliferate as many 
times as the female cells. (Thueson et 
al., in revision) 
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and addition of exogenous IL-2 did not rescue this proliferation defect. The expression 
of CD25 was also decreased in estrogen treated cultures (58). Since CD25 is part of the 
IL-2 receptor, lower expression could lead to a diminished response to IL-2. Estrogen 
has also been shown to directly interfere with the IL-2 receptor expression at the mRNA 
level (59). Treatment with estrogen, or specific agonists for either Estrogen Receptor  
(ER) or Estrogen Receptor  (ER), increases levels of the cAMP response element 
modulator  (CREM) in T cells. CREM is a transcriptional repressor that suppresses 
IL-2 transcription and cytokine production. The suppression of IL-2 transcription by 
CREM occurred more frequently in cells derived from females than cells derived from 
males (59). 
Estrogen can also expand the frequency of CD4+ CD25+ Tregs in vivo (60). Mice 
treated with time-release estrogen pellets had significantly increased levels of Foxp3+. 
Increases in Foxp3 expression correlated with increases in CD25 expression and the 
induction of experimental autoimmune encephalomyelitis (EAE, mouse model of 
multiple sclerosis) in estrogen treated mice resulted in lower disease severity scores 
compared to controls (60). Overall, estrogen appears to have an immunosuppressive 
effect on T cells by causing an increase in Tregs and directly decreasing the activation 
and proliferation of effector T cells. 
Estrogen can also affect other cells of the immune system. Estrogen has been 
shown to increase levels of toll-like receptor 4 (TLR-4) on macrophages and increase 
the production of pro-inflammatory cytokines (61). Targeted disruption of ER abolished 
this effect showing that estrogen was acting through ER to mediate this effect. In 
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contrast to these results, signaling through G-protein coupled estrogen receptor 1 
(GPER-1, formerly known as GPR30) on macrophages decreased expression of TLR-4 
and inhibited a LPS-induced pro-inflammatory response (62). These results show that 
different estrogen receptors can cause different effects on the same cell type and that 
treatment with estrogen (specifically 17--estradiol) can give rise to many different 
outcomes depending on the context of the signaling and the receptors involved. 
Interaction of Atrazine and Estrogen Receptors 
Although ER and ER are classical nuclear estrogen receptors, additional 
receptors including the more recently identified estrogen receptors like G-protein 
coupled estrogen receptor 1 (GPER-1) may play a role in immune modulation. Signaling 
through GPER-1 leads to rapid signaling and transcriptional events (63). It is expressed 
in the central and peripheral nervous systems and has been linked to attenuating 
serotonin receptor signaling (63). GPER-1 can also be found in cardiovascular tissue 
where it causes vasodilation and can decrease blood pressure (63). GPER-1 signaling 
is also involved in thymic atrophy and double positive thymocyte apoptosis (64). GPER-
1 knockout mice treated with estrogen had a reduction in double positive thymocyte 
apoptosis compared to ER and ER knockout mice. This provides evidence that T 
cells can express GPER-1 although expression of GPER-1 has not yet been assessed 
for single positive T cells that have exited the thymus. Previous studies have looked at 
the effects of GPER-1 on various tissues, but its effects on CD4+ T cell biology are less 
understood.  
A study by Yates et al. examining the protective effects of estrogen on EAE 
disease severity identified GPER-1 as a potential mediator of that protection. They 
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found that ER- knockout mice treated with estrogen still displayed reduced disease 
severity, but when GPER-1 knockout mice were treated with estrogen the protective 
effect was lost. This led them to conclude that estrogen mediated the protective effect 
via GPER-1 (65). In subsequent experiments, Blasko et al. treated mice with the GPER-
1 agonist G-1 and found that it decreased EAE disease severity and pro-inflammatory 
cytokine production (66). These results suggest that activation of GPER-1 may be 
immunosuppressive.  
The possibility exists that atrazine and its metabolites could physically interact 
with estrogen receptors like ER, ER or GPER-1 to mediate our previously observed 
effects. However, competitive binding experiments involving these estrogen receptors 
have shown that ATR does not interact with ER or ER (17), but it can weakly interact 
with GPER-1 (67). ATR metabolites have not been shown to interact with ER or ER 
although studies have not examined metabolite interactions with GPER-1 (17). These 
findings, as well as the potential for ATR to increase levels of estrogen, strongly suggest 
that ATR exposure could trigger GPER-1 signaling. Our previous observations have 
shown that phosphodiesterase inhibition alone does not fully replicate the decreased 
CD4+ T cell activation seen in ATR treated cultures (Figure 6) and male-derived cells 
are more sensitive to ATR treatment than female-derived cells (Figure 7). These results, 
as well as the fact that ATR is an endocrine disrupting compound, suggest that the 
more severe ATR-mediated decrease in CD4+ T cell proliferation and activation and 
increase in the frequency of Foxp3+ T cells may involve GPER-1.  
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Thesis Hypothesis and Project Rationale 
 ATR is the most common contaminant of ground and drinking water in the United 
States (1). It can last for extended time periods in soil and water and is easily spread far 
from application sites (22). Biochemically, ATR is a potent PDE inhibitor that increases 
cAMP levels. ATR is also an endocrine disrupting compound that is capable of inducing 
aromatase expression and increasing estrogen levels (12). Previous studies in the 
Wetzel laboratory have investigated the effects of ATR’s PDE inhibitor activity on CD4+ 
T cells and found that pharmacological agents that increase cAMP can inhibit CD4+ T 
cell activation and proliferation. The PDE inhibitor, Pentoxyfilline (PTX), and the non-
cleavable cAMP, dibutyryl cAMP, were used to mimic PDE inhibitor effects of ATR on 
CD4+ T cells. In PTX and dibutyryl cAMP treated cultures, inhibition of CD4+ T cell 
proliferation was comparable to that seen in 30µM ATR treated cultures. However, the 
frequency of activated CD4+ T cells was lower in ATR exposed cultures compared to 
PTX (Figure 6) and dibutyryl cAMP (data not shown) exposed cultures. It was also 
discovered that male-derived cells were more sensitive to ATR exposure than female-
derived cells (Figure 7). Since treatment with ATR displayed a sex bias and decreased 
the frequency of activated CD4+ T cells more than that seen by pharmacologically 
increasing cAMP, we hypothesized that ATR’s EDC activity was involved in the 
decrease of activated CD4
+
 T cells and the increase in Foxp3
+
 regulatory T cells. Since 
ATR is known to via aromatase induction and increase estrogen levels (12), we further 
hypothesized that ATR was acting, in part, via elevated estrogen.  
ATR has not been known to interact with ERα or ERβ but it has been shown to 
weakly interact with GPER-1 (67). GPER-1 became the receptor of interest because it 
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impacts immune cells via decreased TLR4 expression on macrophages (62), and 
GPER-1 triggering by the specific agonist G-1 was protective in experimental 
autoimmune encephalomyelitis (EAE, a mouse model of multiple sclerosis) (66). GPER-
1 triggering also increased cAMP (63), which may be complementing ATR’s PDE 
inhibitor activity. GPER-1 signaling appears to have immunosuppressive effects, but 
how it impacts CD4+ T cells remain elusive. From these observations, we hypothesized 
that the ATR-mediated decrease in CD4+ T cell activation and proliferation and increase 
in frequency of Foxp3+ CD4+ T cells is, in part, due to ATR-mediated elevation of 
estrogen, which then triggers GPER-1 signaling.  
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Materials and Methods 
Cell Culture Reagents 
Murine splenocytes were cultured in complete RPMI 1640 (Sigma, St. Louis, MO) 
containing 10% fetal bovine serum. (Atlanta, Biologicals, Atlanta, GA). RPMI was 
supplemented with L-glutamine, sodium pyruvate, Penicillin G, Streptomycin, 
Gentamycin, phenol red, and MEM essential and non-essential amino acids (Sigma, St. 
Louis, MO). Media was sterile filtered through a 0.2µm filter into an autoclaved 1 liter 
glass bottle. It was stored at 4C and warmed in a 37C water bath prior to use. 
Red blood cells were lysed by incubation in a hypotonic buffer for 5 to 10 minutes 
at room temperature. This buffer, Gey’s solution, was made by mixing 200ml of Solution 
A (35g NH4Cl, 1.85g KCl, 0.595g anhydrous Na2HPO4, 0.12g KH2PO4, 5g Glucose, 
50mg phenol red in 1L of Millipore water), 50ml of Solution B (1.05g MgCl6H2O, 0.35g 
MgSO47H2O, 0.85g anhydrous CaCl2 in 250ml Millipore water) and 50ml Solution C 
(5.63g NaHCO3 in 250ml Millipore water). The volume of the final 1X Gey’s solution was 
adjusted to 1L with 700 ml Millipore water before it was sterile filtered using a 0.2µm 
filter. This final solution was stored at 4C. 
Staining Antibodies 
The following purified, fluorescent-conjugated or biotinylated antibodies were 
purchased from BioLegend (San Diego, CA): CD3 (145.2C11), CD4 (GK1.5), CD25 
(3C7 and PC61), CD28 (37.51), CD62L (MEL-14), CD69 (H1.2F3) , PD-1 (RMP1-30 
and 29F.1A12), and Foxp3 (150D). In addition, antibodies specific for V3 (KJ25) and 
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CD69 (H1.2F3) were purchased from BD Biosciences (San Jose, CA). Staining for 
Foxp3 was done using the BioLegend AlexaFluor 488 Anti-mouse/rat/human Foxp3 
Flow Kit. To monitor proliferation, cells were stained with 5-(and 6-)carboxy-2’,7’-
dichlorofluorscein diacetate succinmidyl ester (CFSE) or Cell Trace Violet (CTV) (Life 
Technologies, Eugene, OR) according to the manufacturer’s protocol on day 0. Day 0 
stains (stained, unstained, isotype) were also removed from the whole spleen 
preparation before CFSE/CTV staining. A single-color control for CFSE and CTV was 
made by removing 106 cells from an untreated culture on day 1. Live cells were 
assessed by flow cytometry or cells were fixed for 30 minutes using 4% 
paraformaldehyde (PFA) and 0.5% Glutaraldehyde in PBS. Fixative was washed out 
using FACS buffer (PBS with 2% and bovine serum albumin (BSA) and 0.1% sodium 
azide) and resuspended in 300µL FACS buffer. This sample stored at 4C in the dark 
until analyzed. Day 0 samples were, fixed and stored at 4C in the dark until analyzed 
with day 4 samples. Single color controls were made using UltraComp ebeads 
(eBioscience, San Diego, CA).  
Mice  
B10.BR mice were purchased from (Jackson Labs, Bar Harbor, ME.). AD10 
mice, specific for pigeon cytochrome C peptide 88-104 presented by I-E
k
 and reactive 
against moth cytochrome peptide 88-103 (68) were provided by Dr. David Parker at 
Oregon Health and Science University.  
AD10 mice were maintained as heterozygotes. To identify transgenic offspring, 
AD10 pups were genotyped by PCR using primers specific for the recombined V3 and 
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J2 of the AD10 TCR  chain. Toe tissue samples were taken from AD10 x B10.BR 
litters before 7 days of age for identifying and typing purposes. Toe tissue was digested 
using 40µL Toe/Ear digestion buffer and 2µL proteinase K. After a 1 hour incubation at 
55°C, 158µL of autoclaved water was added, the sample was lightly vortexed and then 
heated at 95°C for 10 minutes to inactivate the proteinase K. Samples were then stored 
at -20°C until PCR analysis. For long-term storage, DNA samples were stored at -80°C. 
B10.BR and AD10 mice were kept in specific pathogen free (SPF) housing at the 
University of Montana and allowed food and water ad libitum, in accordance with the 
UM Institutional Animal Care and Use Committee (IACUC) guidelines. 
Preparation of Atrazine, Estrogen, and Experimental compounds 
To prepare a 60 mM stock solution of atrazine, 250mg of atrazine (Chem 
Service, Chester PA) was resuspended in 19.3ml of 100% ethanol (Sigma, St. Louis, 
MO). After resuspending the atrazine, the solution was vortexed until a homogenous 
suspension was made. The stock was then aliquoted and stored at -80°C. When used 
in experiments, an aliquot of the stock solution was thawed and vortexed. It was then 
diluted 1:2 in 100% ethanol to form a 30 mM working solution. This solution was diluted 
1:1000 in complete RPMI in the 6-well plates, giving a final concentration in the wells of 
30µM in 0.1% ethanol. For the vehicle controls, EtOH was added to a final 
concentration of 0.1%.  
The phosphodiesterase inhibitor Pentoxyfilline was purchased from Tocris 
Biological (Minneapolis, MN) and resuspended in ethanol to create a stock solution of 
100mM. For experiments the final solution in the wells was a 250µM, which was 
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generated by addition of 12.5µL of the stock 100 mM solution was added to 5ml cell 
cultures.  
To prepare the estrogen stock solution, 17-β-estradiol (E2) was purchased from 
(Sigma, St. Louis, MO) and resuspended in 100% ethanol. It was then further diluted 
with PBS to make the stock a 500ng/ml concentration. For experiments, the 500 ng/ml 
stock solution was diluted in complete RPMI to a final concentration of 5, 10, or 25 
ng/ml. Note, new estrogen stock solutions were made monthly. 
The Estrogen receptor  agonist PPT (4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-
triyl)trisphenol) was purchased from Tocris Biologicals (Minneapolis, MN). It has a 410 
fold selectivity for ER over ER and has an EC50 of ~200 pM. To prepare a 5mM stock 
solution, 10 mg were resuspended in 5.1ml of 100% ethanol. Working 1000X solutions 
were prepared by dilution in 100% ethanol and these solutions were then diluted 1:1000 
into RPMI so that the final concentration of ethanol was 0.1%.  
The aromatase inhibitor YM511 (4-[[(4-Bromophenyl)methyl]-4H-1,2,4-triazol-4-
ylamino]benzonitrile) was purchased from Tocris Biologicals (Minneapolis, MN) and 
resuspended in 100% ethanol to create a 20mM stock solution. The stock solution was 
diluted to 10µM or 5µM in 100% ethanol and diluted 1000 X in complete RPMI to give 
the desired final concentration. YM511 has an IC50 of 0.4nM in rat ovaries and 
decreases estrogen levels with an IC50 of 0.13nM (69). 
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GPER-1 agonist and antagonist solution preparation 
The GPER-1 agonist G-1 and the GPER-1 antagonists G-15 and G-36 were 
purchased from purchased from Tocris or Azano Biotech (Albuquerque, NM). 10mM 
stock solutions of each of these reagents was made by resuspending in an appropriate 
amount of dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO). For G-1 and G-36, 10mg 
were resuspended in 2.4 ml DMSO. For G-15, 10mg was resuspended in 2.7 ml DMSO. 
These 10mM solutions were diluted to 1000X working solutions in DMSO and then 
diluted 1:1000 into complete RPMI so that the final solutions contained 0.1% DMSO. G-
1 has a Ki of 11nM and an EC50 of 2nM and displays no activity with ER or ER up to 
10M (70). G-15 has a half maximal inhibitory concentration (IC50) of 190nM (71). G-36, 
a newly generated and more specific variant of G-15 has an IC50 of 112nM (72). 
 In vitro exposure primary cultures 
In the experiments described in this thesis, primary murine splenic cultures were 
stimulated in the presence of atrazine, the indicated compounds, or vehicle-only 
controls for 4 days. To establish single-cell splenocyte cultures on day 0, spleens were 
harvested from mice over 6 weeks of age and placed in Hanks’ Balanced Salt Solution 
(Sigma, St. Louis, MO). The spleen was then placed in a sterile petri dish and 
mechanically ruptured by gentle grinding between the frosted sides of two sterile glass 
microscope slides in 10ml of RPMI. Cells were centrifuged at 500xg for 7 minutes. 
Supernatant was aspirated off and red blood cells were subsequently lysed using 5ml of 
hypotonic Gey’s solution. After 5 minutes in Gey’s solution, 5ml of RPMI was added and 
cells were centrifuged for 500xg for 7 minutes. Supernatant was aspirated off and cells 
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were resuspended in 10ml RPMI. A small aliquot of cells was then diluted with trypan 
blue and directly counted using a hemocytometer.  
AD10 cells were stimulated with 2.5 µM Moth Cytochrome C (MCC88-103) peptide, 
while non-transgenic B10.BR cells were stimulated using plate bound anti-CD3 (145-
2C11) and anti-CD28 (37.51) antibodies, both at 10µg/ml. To coat plates with antibodies 
6-well tissue culture dishes (Greiner, Monroe, NC) were incubated with anti-CD3 and 
anti-CD28 in PBS for 2 hours at 37°C. The plates were then sealed to prevent 
evaporation and stored at 4°C until used. Before use, the antibody solution was 
removed and discarded. The wells were washed with 3ml of PBS and allowed to dry at 
room temperature before cells were added. 
Cells were resuspended at 1.6x106 or 2x106 cells per ml and 5ml were plated in 
six well tissue culture dishes and the indicated treatment compounds were added. 
Vehicle-only control cultures were established containing 0.1% EtOH or 0.1% DMSO, 
which corresponded to the final concentration of vehicle in experimental samples. The 
control and treatment cultures were maintained at 37°C with 5% CO2 for 4 days. On day 
4, a small aliquot of cell supernatant was collected and filtered to remove any cells and 
stored at -20C for analysis of estrogen levels. Viable lymphocytes were recovered via 
density centrifugation using LymphoLyte M (Cedar Lane, Burlington, NC). Cells were 
counted using a hemocytometer and Fc Receptors were blocked by addition of anti-
CD16 antibodies (Fc Block, 1:100 dilution, BioLegend, San Diego, CA) for 15 minutes. 
Cells were then stained with 1:100 dilutions of various combinations of extracellular 
stains (CD4, CD69, CD25, Vβ3, CD62L, and PD-1) for 25 minutes. When necessary, 
cells were stained with fluorochrome-conjugated secondary antibodies for an additional 
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15 minutes and washed once with FACS buffer. In some experiments, cells were fixed 
and stained for intracellular Foxp3 using the Foxp3 staining kit (BioLegend, San Diego, 
CA.). Briefly, cells were incubated for 20 minutes in 1X Fix/Perm buffer before 3 washes 
with FACS buffer. The cells were incubated an additional 15 minutes in 1X Perm buffer, 
washed and stained with a 1:20 dilution of anti-Foxp3 antibody for 30 minutes. Fixed 
samples were stored for up to 3 days in the dark at 4°C before analysis using a 
FACSAria IIu (Becton Dickenson, San Jose, CA) in the University of Montana 
Fluorescence Cytometry Core facility. If cells were antibody stimulated, 10,000 CD4+ 
cells were collected from each sample. If cells were stimulated via peptide, then 10,000 
CD4+ Vβ3+ cells were collected from each sample. Data was analyzed after using 
FlowJo Software version 8.8.7 (Treestar, Inc, Ashland, OR). 
Statistical Analysis 
To compare different treatment groups, data was analyzed using an unpaired student’s t 
test on Microsoft Excel 2007. Values of p0.05 were considered statistically significant.  
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Results 
Atrazine prevents the down-regulation of CD62L and up-regulation of 
Programmed Death 1 (PD-1) 
Our laboratory has previously found that in vitro exposure to 30µM ATR during 
antigen-recognition significantly reduced expression of CD25 and CD69 on CD4+ T cells 
(Thueson et. al. in revision). To further characterize the activation status of our CD4+ T 
cells in culture, we examined expression of CD62L and programmed death-1 (PD-1), 
(Figures 8 and 9). CD62L is expressed at high levels on naïve cells and expression 
decreases upon activation. PD-1 is a negative co-stimulatory molecule on Tregs and 
CD4+ T cells whose expression is up-regulated upon activation (73). Primary 
splenocytes were antibody stimulated in the presence of 50µM, 30µM, 10µM ATR or the 
ethanol only vehicle control (Figure 8). As seen in Figure 8, there is a dose-dependent 
increase in CD62L, indicating that at higher ATR concentrations fewer T cells were 
activated. Upon treatment with 50 µM ATR, 66.5% of cells expressed CD62L whereas 
with the ethanol control only 22.8% were CD62L+. In addition, 50µM of ATR significantly 
reduced T cell recovery from the cultures (data not shown). The 30µM ATR treatment 
showed a moderate ATR phenotype with 53.3% of cells being CD62L+, while 10µM ATR 
treatment resulted in a minimal ATR effect with 38.3% CD62L+. Based upon these and 
previous observations from the Wetzel laboratory, 30µM of ATR was chosen for 
subsequent experiments, unless otherwise noted, because it resulted in the most 
severe phenotype without significantly increasing cell death (data not shown). 
Treatment with 30µM of ATR decreased expression of PD-1, with only 66.8% of CD4+ T 
cells expressing PD-1 compared to 92.7% in the ethanol only control (Figure 9). The 
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results from Figures 8 and 9 are consistent with our previous CD25 and CD69 data that 
showed that ATR exposure inhibited CD4+ T cell activation in vitro. 
 
 
Figure 8: In vitro ATR exposure inhibits CD62L down-modulation in a dose-dependent manner. 
Cells were stimulated with anti-CD3 and anti-CD28. Antibodies and gated on CD4
+
 T cells. B10.BR 
splenocytes were exposed to 50 µM (green), 30 µM (orange), or 10µM (blue) ATR or the ethanol vehicle 
control (shaded grey). CD62L expression on Day 4 is displayed in the left panel. The region marker 
indicates the CD62L
+
 population. Table indicates the Mean Fluorescence Intensity (MFI) and the 
frequency of CD62L
+
 cells. Data representative of two separate experiments. 
 
Figure 9: In vitro ATR exposure inhibits PD-1 expression. Cells were stimulated with plate bound 
antibodies and gated on CD4
+
 V3
+
 T cells. AD10 splenocytes were exposed to 30µM ATR (orange) or 
the ethanol vehicle control (shaded grey). PD-1 expression on Day 4 is displayed in the left panel. The 
region marker indicates the PD-1
+
 population. Table indicates the Mean Fluorescence Intensity (MFI) and 
the frequency of PD-1
+
 cells. Data representative of three separate experiments. 
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PTX causes an increase in the frequency of Foxp3
+
 CD4
+
 T cells 
On a biochemical level, atrazine is a potent phosphodiesterase inhibitor, which 
results in significant increases in cAMP (16). Previous experiments used the chemical 
PDE inhibitor pentoxyfilline (PTX) and cell permeant, non-cleavable cAMP analog 
dibutyryl cAMP (dbc-AMP) to increase the level of intracellular cAMP to assess the role 
of elevated cAMP in the ATR-associated T cell phenotype (Figure 6). Those 
experiments showed that the ATR phenotype of decreased T cell activation and 
proliferation could partially, but not completely, be replicated by elevating cAMP levels 
pharmacologically. The frequency of Foxp3+ cells was not previously assessed. Here 
we observed that the increase in Foxp3+ regulatory T cells (Tregs) seen with ATR 
treatment was replicated by PTX as seen in Figure 10. The CD4+ T cells from the 
250µM PTX exposed cultures had 2.3 times more Foxp3+ CD4+ T cells compared to the 
ethanol control. This is comparable to, and consistent with, the 2-5 fold increase in 
Foxp3+ cells seen in cultures treated with 30µM ATR. 
 
Figure 10: In vitro PTX exposure increases the frequency of Foxp3
+
 T cells. AD10 splenocytes were 
exposed to 250µM PTX (green) or the ethanol vehicle control (shaded grey). Foxp3 expression on day 4, 
CD4
+
V3
+ 
gated
 
T cells is displayed in the left panel. The region marker indicates the Foxp3
+
 population. 
Table indicates the Mean Fluorescence Intensity (MFI) and the frequency of Foxp3
+
 cells. Data 
representative of two separate experiments. 
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To examine the underlying mechanism for the observed 2-5 fold increase in the 
frequency of Foxp3+ cells in the PTX and ATR cultures, we examined the proliferation of 
the Tregs. The Foxp3
+ CD25+ Tregs proliferated, although not to the same extent as cells 
in the ethanol-only control (Figure 11). Since the proliferation of Tregs is less than the 
ethanol controls but the frequency of Tregs is increased 2-5 fold, the increase in the Treg 
population is not due solely to Treg proliferation. The increase in Foxp3
+ Treg frequency, 
therefore, is likely due to a combination of the expansion of natural, thymus-derived Treg 
(nTreg) and conversion of CD4
+ Teff cells into Tregs (induced Tregs, iTreg). 
 
Figure 11: In vitro ATR and PTX exposure decreases proliferation of CD25
+
 Foxp3
+
 CD4
+
 T cells. 
AD10 splenocytes were exposed to 250µM PTX (green) or 30µM (orange) ATR or the ethanol vehicle 
control (shaded grey). Proliferation of CD4
+
V3
+
 CD25
+
 Foxp3
+ 
gated T cells on day 4 is displayed in the 
left panel. Cells were stained with CTV to monitor proliferation. The region marker indicates the undivided 
population. Percent undivided indicates cells that have not divided or have divided only a few times. Table 
indicates the Mean Fluorescence Intensity (MFI) and frequency of undivided cells. Data representative of 
two separate experiments. 
Estrogen causes a decrease in proliferation and activation of CD4
+
 T 
cells.  
Our previous results show that cells from male mice are more severely affected 
by ATR exposure than cells from female mice (Figure 7). Combined with differences in 
proliferation and activation upon treatment with PTX and ATR, this suggested that 
increased cAMP was not solely responsible for the observed ATR effects. Because of 
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the observed male/female difference and the fact that ATR is an estrogen disrupting 
compound that is known to elevate estrogen levels (74), we explored the possibility that 
estrogen could be involved in the atrazine-mediated effects. To determine whether 
estrogen could affect the activation of CD4+ T cells, estrogen was added to the cell 
cultures at 5 ng/ml, 10 ng/ml and 25 ng/ml on day 0. The results in Figure 12 confirm 
that elevated estrogen can inhibit CD4+ T cell activation and proliferation. Figure 12A 
shows that 25ng/ml estrogen decreased T cell proliferation 12-fold, which is comparable 
to the effects of 30µM ATR. The addition of 10ng/ml and 5ng/ml of estrogen also 
decreased proliferation (5 fold and 7.8 fold, respectively), although not as severely as 
25ng/ml. Interestingly, 5ng/ml of estrogen was slightly more potent than 10ng/ml, 
consistent with non-monotonic effects (14). 
In addition to proliferation, we examined the activation of T cells in the presence 
of estrogen. As seen in Figure 12B, 25ng/ml reduced the frequency of CD25+ cells. This 
is similar to the effects observed with 30µM ATR. The 5ng/ml and 10ng/ml estrogen 
treatments also decreased the MFI of CD25 and increased the frequency of CD25- 
cells, but not as severely as 25ng/ml. Figure 12C shows that all three estrogen 
concentrations tested also decreased expression of PD-1 compared to the ethanol only 
control. As with proliferation and CD25 expression results, the frequency of PD-1+ cells 
in the 25ng/ml group was comparable to that seen with the 30µM ATR treatment. 
Together, the data from Figure 12 showed 25ng/ml of estrogen decreased T cell 
activation and proliferation to a comparable extent with 30µM ATR. This finding 
supports the hypothesis that estrogen is contributing to the observed ATR phenotype.  
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Figure 12: In vitro estrogen exposure causes decreased proliferation and activation. AD10 
splenocytes were exposed to 25ng/ml (pink), 10ng/ml (green), 5ng/ml (blue) or 30µM (orange) ATR or the 
ethanol vehicle control (shaded grey). A. Cells were stained with CFSE to monitor proliferation. Estrogen 
was diluted with PBS. Table below shows MFI and percentage of undivided cells. Percent undivided 
indicates cells that have not divided or have divided only a few times. B and C. CD25 and PD-1 were 
used to show T cell activation within each treatment group. Table below B shows MFI and percentage of 
CD25
+
 T cells. Table to the right of C shows MFI and percentage of PD-1
+
 T cells. Cells were stimulated 
with plate-bound anti-CD3 and anti-CD28. Data representative of 2 separate experiments. 
Estrogen synergizes with Atrazine to further decrease CD4
+
 T cell 
activation and proliferation 
Our previous results show that use of pharmacological reagents that increase 
cAMP and addition of exogenous estrogen mimicked the ATR effects on CD4
+
 T cells. 
Since it would be expected, based upon its biochemical activities, that ATR treatment 
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would lead to increases in both cAMP and estrogen, we next combined these 
treatments to see if there was any additive or synergistic effects. Cells were activated in 
the presence of a suboptimal concentration of ATR (15µM) with or without addition of 
25ng/ml of estrogen. As seen in Figure 13, 15µM ATR treatment resulted in 38.2% of 
cells remaining undivided. Addition of 25ng/ml of estrogen to the 15µM ATR cultures 
inhibited prolferation in 95% of the cells. By comparison, 53.6% of undivided cells in 
25ng/ml estrogen cultures alone did not divide (Figures 12A and 13A). The significant 
increase in the percentage of undivided cells in the cultures containing 15µM ATR and 
25ng/ml estrogen are indicative of a synergistic effect between these compounds. 
In additon to examining the effects on proliferation, the effects of 15µM ATR and 
25ng/ml estrogen on the activation state of CD4+ T cells, as measured by CD25 and 
PD-1 expression, was also assessed. As with proliferation, addition of 25mg/ml 
estrogen with 15µM ATR decreased expression levels of CD25 by an additional 8 fold 
and PD-1 by 1.5 fold on the activated CD4+ T cells compared to 15μM ATR alone 
(Figures 13B & 13C). The region marker in Figure 13B indiates the CD25+ T cell 
population. Upon treatment with 15µM ATR, 63.1% of the cells were CD25+ while the 
addition of 25ng/ml of estrogen to 15µM ATR reduced that to 26.8% CD25+ T cells 
(Figure 13B). As with the frequency of CD25+ cells, the frequency of PD-1+ cells was 1.5 
fold lower in the 25ng/ml estrogen and 15µM ATR treatment group (43.7% PD-1+) 
compared to the 15µM ATR treatment (66.2% PD-1+) or 25ng/ml estrogen treatment 
(70.7%, Figure 12C). The decreased levels of CD25 and PD-1 in the culture containing 
estrogen and atrazine, along with the proliferation data in Figure 13A, show that 
estrogen can further decrease proliferation and activation in the presence of atrazine. 
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Figure 13: Cells cultured with Atrazine + estrogen display decreased proliferation and activation. 
B10.BR splenocytes were exposed to 25ng/ml estrogen (pink), 15µM ATR + estrogen (red), 15µM ATR 
(orange), or an EtOH only control (shaded grey). Cells were stimulated with plate-bound anti-CD3 and 
anti-CD28 and for 4 days and then gated on live CD4
+
 T cells. A. Cells were stained with CFSE to monitor 
proliferation (left panel). Table shows MFI and percentage of undivided cells. Region markers indicated 
percentage of undivided cells. Percent undivided indicates cells that have not divided or have divided only 
a few times. B and C. CD25 and PD-1 expression on cells from the cultures in A. Tables indicate MFI and 
percent of CD25
+
 and PD-1
+
 cells (right panels). Region markers indicate percent of CD25
+
 and PD-1
+
 
cells. Data representative of 2 separate experiments. 
Signaling through GPER 1, but not ERα, mimics the decreased activation and 
proliferation seen with Atrazine 
Figures 12 and 13 suggest that elevated estrogen levels inhibit CD4+ T cell 
activation and proliferation and that this might play a role in the observed ATR 
phenotype. To begin to understand this potential mechanism, we next examined which 
estrogen receptor(s) might be involved. Previously published reports have suggested 
both estrogen receptor α (ERα) and the G-protein coupled estrogen receptor (GPER-1) 
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are involved in estrogen-mediated control of T cell activity (75, 66)., We began by 
culturing cells in the presence of 5nM, 1nM, or 0.5nM of the selective ERα agonist PPT 
to determine if signaling through ERα could inhibit proliferation and/or activation. PPT 
has an EC 50 of 200pM and is 410 times more selective for ERα over estrogen receptor 
β (ERβ) (76). 
As shown in Figure 14, PPT treatment resulted in no significant changes in CD4+ 
T cell proliferation, CD25 expression, or the frequency of Foxp3+ T cells. The CD4+ T 
cells in the PPT cultures proliferated nearly identically to the ethanol control (Figure 
14A) and had similar CD25 expression (Figure 14B). The frequency of Foxp3 was 
slightly lower than the ethanol control although the difference was not significant (Figure 
14C). In contrast, the 30µM ATR treatment left 40.5% of cells undivided, reduced the 
frequency of CD25+ T cells by 1.2 fold and increased the frequency of Foxp3+ T cells 
more than 6-fold. Based on the data from Figure 14, ERα stimulation does not appear to 
mimic the ATR effects seen on CD4+ T cells. 
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Figure 14: Cells cultured with the ER agonist PPT did not display decreased proliferation and 
activation. AD10 splenocytes were exposed to 5nM PPT (green), 1nM PPT (pink), 0.5nM PPT (blue), 
30µM ATR (orange), or the EtOH control (shaded grey). Cells were gated on CD4
+
 V3
+
 T cells. A. Cells 
were stained with CTV to monitor proliferation (left panel). Table shows MFI and percentage of undivided 
cells. Region marker indicates percentage of undivided cells. Percent undivided indicates cells that have 
not divided or have divided only a few times. B. CD25 was used to indicate T cell activation (left panels). 
Table indicates MFI and percent of CD25
+
 cells (right panel). Region marker indicates percent of CD25
+
 
cells. C. Foxp3 was stained using Biolegend’s Foxp3 staining kit (left panel). Table indicates MFI and 
percent of Foxp3
+
 cells (right panel). Region marker indicates Foxp3
+
 cells. Data representative of 2 
separate experiments. ** p≤0.05 compared to EtOH, 
&
 p≤0.05 compared to ATR 
Since triggering ER using PPT didn’t affect activation or proliferation of the 
CD4+ T cells, we next examined the potential role of GPER-1. The GPER-1 agonist, G-
1, has been shown to decrease the severity of EAE in mice by increasing the production 
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of anti-inflammatory cytokines (65). Since GPER1 triggering has immunosuppressive 
effects, it is possible that it may be playing a role in the observed ATR-associated, CD4+ 
T cell inhibition. To test this possibility, spleen cells were treated with 10nM, 100nM, 
1µM G-1 or DMSO vehicle control. During the 4 day activation culture. As seen in 
Figure 15A, treatment with 10nM and 100nM of G-1 did not affect CD4+ T cell 
proliferation. However, treatment with 1µM G-1 increased the frequency of non-dividing 
CD4+ T cells by approximately 4 fold compared to the DMSO control. In comparison, the 
atrazine control increased the frequency of dividing cells by approximately 22 fold 
compared to the ethanol control (Figure 15B). The effects of 1µM G-1 data are similar to 
the results of treatment with the suboptimal 3µM concentration of ATR (data not shown). 
G-1 can mimic the effects we see with lower concentrations of ATR suggesting that it 
has inhibitory effects on CD4+ T cells. A direct comparison of CD4+ T cell proliferation in 
the 1µM G-1 and ATR cultures is shown in Figure 15C. The mean fluorescence intensity 
(MFI) of 1μM G-1 and 30μM ATR were statistically significant compared to their 
respective vehicle controls. It is interesting to note that CD4+ T cell recovery was 
decreased in both 1µM G-1 and ATR cultures. 
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Figure 15: Cells cultured with the GPER-1 agonist, G-1, display decreased proliferation. Cells were 
stimulated with 2.5µM MCC peptide and gated on CD4
+ 
V3
+
 T cells. AD10 splenocytes were exposed to 
1µM G-1 (green), 100nM G-1 (pink), 10nM G-1 (blue), 30µM ATR (orange), an EtOH control (shaded 
grey) or a DMSO vehicle control (shaded cyan, cyan line in Part C). Cells were stained with CTV to 
monitor proliferation. A and B. Tables shows MFI and percentage of undivided cells. Region markers 
indicate percentage of undivided cells. Percent undivided indicates cells that have not divided or have 
divided only a few times. C. Overlay of 1µM G-1 and 30µM ATR treatment groups with EtOH and DMSO 
controls. Data representative of 2 separate experiments. * p≤0.05 compared to DMSO, ** p≤0.05 
compared to EtOH, 
&
 p≤0.05 compared to ATR  
 
We next assessed the role GPER-1 signaling may have on T cell activation by 
looking at CD25 expression. Figure 16A shows that exposure to 1µM G-1 did not 
significantly alter T cell activation, as measured by the frequency of CD25+ CD4+ T 
cells. There were 90.3% CD25+ T cells in the G-1 culture compared to 93.5% for the 
DMSO control. In comparison, 30µM ATR treatment resulted in a bimodal population 
with 34% of cells being CD25- (Figure 16B). GPER-1 signaling with G-1 does not 
significantly decrease expression of CD25 on CD4+ T cells, suggesting that is does not 
directly impact T cell activation. 
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Figure 16: Treatment with 1µM G-1 (left, A) and ATR (middle, B) decrease the expression of CD25 
in the cell culture. Cells were gated on CD4
+ 
V3
+
 T cells. AD10 splenocytes were exposed to 1µM G-1 
(green), 30µM ATR (orange), an EtOH control (shaded grey) or a DMSO vehicle control (shaded cyan). 
Table on the right shows MFI and percentage of CD25
+
 cells. Region markers indicate CD25
+
 cells. 
*p≤0.05 compared to DMSO, ** p≤0.05 compared to EtOH, 
&
 p≤0.05 compared to ATR 
We also examined whether 1µM G-1 treatment would alter the frequency of 
Foxp3+ CD4+ T cells. Figure 17A shows that treatment with G-1 increased the frequency 
of Foxp3+ CD4+ T cells 2 fold (7.3% compared to 3.4%). Unfortunately the increase in 
Foxp3+ cells upon treatment with G-1 was variable, as seen in Figure 17B. In some 
experiments, G-1 did not significantly alter Foxp3+ cell frequencies. Thus, while we can 
confidently conclude that 1µM G-1 inhibits CD4+ T cell proliferation, we cannot conclude 
that GPER-1 stimulation with G-1 increases the frequency of CD4+ Foxp3+ Tregs. 
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Figure 17: Varied effects of Foxp3 expression upon treatment with 1µM G-1. Cells were gated on 
CD4
+
 V3
+
 T cells. AD10 splenocytes were cultured with 1µM G-1 (green), 30µM ATR (orange), DMSO 
control (shaded cyan), or EtOH control (shaded grey). A. 1µM G-1 (left) and 30µM ATR (right) increased 
the frequency of Foxp3
+
 T cells (left panel). Table indicates MFI and percent of Foxp3
+
 cells. Region 
marker indicates Foxp3
+
 cells. B. Treatment with 1µM G-1 did not significantly increase the frequency of 
Foxp3
+
 CD25
+
 Tregs compared to the DMSO control. Data representative of 2 separate experiments. 
*p≤0.05 compared to DMSO, ** p≤0.05 compared to EtOH, 
&
 p≤0.05 compared to ATR 
 
Figure 18: In vitro G-1 exposure slightly decreases proliferation of CD25
+
 Foxp3
+
 CD4
+
 T cells. 
Cells were gated on CD4
+
V3
+
 CD25
+
 Foxp3
+ 
T cells. AD10 splenocytes were exposed to 1µM G-1 
(green) or DMSO (shaded cyan). Proliferation on Day 4 is displayed in the left panel. Cells were stained 
with CTV to monitor proliferation. The region marker indicates the undivided population. Percent 
undivided indicates cells that have not divided or have divided only a few times. Table indicates the Mean 
Fluorescence Intensity (MFI) and frequency of undivided cells. Data representative of two separate 
experiments. 
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Since we observed a slight defect in Treg proliferation upon treatment with PTX 
and ATR (Figure 11), we assessed whether this defect was present in 1µM G-1 treated 
cultures. As seen in Figure 18, Treg proliferation was slightly decreased (1.86 fold 
increase in percentage of undivided cells, 2.3 fold higher MFI) compared to the DMSO 
control. As seen in Figure 11, PTX and ATR increased the MFI of proliferation by 3-4 
fold indicating that Tregs underwent fewer divisions than the ethanol control. The 
difference in Treg proliferation upon GPER-1 triggering with G-1 was comparable to the 
differences seen in Treg proliferation upon treatment with ATR and PTX. Thus, in 
experiments where G-1 treatment increased the frequency of Foxp3+ CD4+ T cells, it 
negatively affected Treg proliferation.  
The GPER-1 agonists, G-15 and G-36, do not alleviate the ATR-
mediated effects on CD4
+
 T cells 
To further investigate the potential of GPER-1 signaling in ATR treated cultures, 
we antagonized GPER-1 with the antagonist G-15. We reasoned that if GPER-1 was 
involved in the ATR-mediated decrease in activation and proliferation then antagonizing 
the receptor should alleviate the effect. Since ATR is still inhibiting PDE and elevating 
cAMP, we predicted that there would be a small phenotypic rescue instead of a 
complete reversal of the ATR phenotype. In these experiments we used 15µM ATR 
rather than 30µM because it gave a more moderate phenotype, which would likely be 
more sensitive to GPER-1 blockade than the much more severe 30µM treatment 
phenotype. Cells were stimulated with anti-CD3 and anti-CD28 in the presence of 15µM 
ATR and various concentrations of the GPER-1 antagonist G-15 for four days. Of note, 
upon analysis of the vehicle controls, the antibody stimulation resulted in suboptimal T 
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cell stimulation (Figures 19 and 20) since proliferation and CD69 expression were 
slightly inhibited compared to antigen stimulated cultures (Figures 14,15,and 16). 
Contrary to the prediction, the results in figures 19 and 20 show that addition of 
G-15 to 15µM ATR actually potentiated the ATR phenotype rather than reversing the 
ATR effects. Treatment with 15µM ATR typically gives an intermediate phenotype, but 
when combined with G-15, it mimicked the 30µM ATR results. The dose response in the 
G-1 and 15μM ATR cultures showed that 10nM G-15 + 15μM ATR inhibited CD4+ T cell 
proliferation 2.8 fold more than the 15μM ATR + DMSO control (Figure 19). Since G-15 
has been shown to lose GPER-1 selectivity at higher concentrations (77), the 1μM G-15 
treatment may be triggering different estrogen pathways causing decreased severity 
compared to lower G-15 concentrations. The increased severity of 10nM G-15 in 15μM 
ATR cultures may also be the result of a non-monotonic (14) dose response since its Ki 
is relatively low (Ki=20nM) (78). These results indicate that treatment with G-15 
increased the severity of our ATR treatment, but higher concentrations of G-15 were 
less potent. Inhibiting GPER-1 with G-15 in the absence of atrazine had no adverse 
effect on T cell proliferation (5.5% undivided) compared to the DMSO control (7% 
undivided, Figure 19C). 
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Figure 19: The GPER-1 agonist (G-15) in the presence of ATR, severely inhibits CD4
+
 T cell 
proliferation. Cells were stimulated with plate bound anti-CD3 and anti-CD28 antibodies and gated on 
CD4
+
 T cells. B10.BR splenocytes were cultured with 1µM G-15 + 15µM ATR (blue), 100nM G-15 + 15µM 
ATR (green), 10nM G-15 + 15µM ATR (brown), 1µM G-15 only (pink), 15µM ATR (orange), 15µM ATR + 
DMSO (red), EtOH (shaded grey), DMSO (shaded cyan), or EtOH + DMSO (light purple). A. Cells were 
stained with CTV to monitor proliferation. Treatment with G-15 + ATR decreased the proliferation of CD4
+
 
T cells more than ATR treatment alone (Part B). C. Treatment with 1µM G-15 alone had no adverse 
effects on CD4
+
 T cells. Table shows MFI and percentage of undivided cells. Region markers indicate 
percent of undivided cells. Percent undivided indicates cells that have not divided or have divided only a 
few times. Data representative of 2 separate experiments. 
In addition to inhibiting proliferation, treatment with 15µM ATR and G-15 also 
inhibited CD69 expression (Figure 20), with 10nM G-15 and 15µM ATR having the 
fewest CD69
+
 CD4
+
 T cells and a significantly reduced per cell CD69 expression (MFI) 
(Figure 20A). Treatment with 10nM G-15 + 15μM ATR increased the frequency of 
CD69- CD4+ T cells 4.9 fold while 1μM G-15 + 15μM ATR increased the frequency of 
CD69- CD4+ T cells by 2.1 fold compared to the 15μM ATR + DMSO control. 100nM G-
15 and 15μM ATR gave an intermediate phenotype between the 10nM G-15 and 15μM 
ATR and 1μM G-15 and 15μM ATR cultures. Again, this is consistent with a non-
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monotonic dose-response curve. The frequency of CD69- cells in the G-15 treated 
cultures was also much higher than the frequency CD69- cells in the 15µM ATR (17.4%, 
Figure 20B) and EtOH + DMSO control (27.2%, Figure 20A) cultures. Treatment with 
15μM ATR and DMSO did not alter the 15μM ATR effect showing that the increased 
severity caused by 15μM ATR and G-15 is not due to addition of DMSO into ATR 
cultures, but is due to the G-15. Interestingly, treatment with 1µM G-15 alone did not 
affect CD4+ T cell proliferation or activation showing that antagonizing GPER-1 with G-
15 in the absence of ATR had no effect on CD4+ T cells (Figure 20C). Figures 19 and 
20 suggest that G-15 treatment did not antagonize GPER-1. This may have been due to 
and non-specific binding of G-15 to other estrogen receptors on the CD4+ T cells. 
.   
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Figure 20: The GPER-1 agonist, G-15, severely inhibits CD69 expression. Cells were stimulated with 
plate bound anti-CD3 and anti-CD28 antibodies and gated on CD4
+
 T cells. B10.BR splenocytes were 
cultured with 1µM G-15 +15µM ATR (blue), 100nM G-15 + 15µM ATR (green), 10nM G-15 + 15µM ATR 
(brown), 1µM G-15 only (pink), 15µM ATR (orange), 15µM ATR + DMSO (red), EtOH (shaded grey), 
DMSO (shaded cyan), or EtOH + DMSO (light purple). A. Treatment with G-15 + ATR decreased the 
activation of CD4
+
 T cells more than ATR treatment alone (Part B). C. Treatment with 1µM G-15 alone 
had no adverse effects on CD4
+
 T cells. Table shows MFI and percentage of CD69
+
 cells. Region 
markers indicate CD69
+
 cells. Data representative of 2 separate experiments. 
While the G-15 data was initially difficult to decipher, the structure of G-15 allows 
it to interact with ERα and ERβ, triggering them while blocking GPER-1 (77). Thus 
drawing conclusions from the G-15 results is difficult. To better test the role of GPER1 
by antagonizing the receptor we used a new, selective GPER-1 antagonist, G-36, that 
was recently synthesized and became available in April 2014 (77). G-36 has an 
additional functional group that has been shown to limit interaction with other estrogen 
receptors (77). The G-15 GPER1 antagonism experiments were repeated with G-36 
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although 30µM ATR was used instead of 15µM ATR in order to allow for a direct 
comparison with our well characterized ATR phenotype. 
As with G-15, when G-36 was added to cultures containing 30µM ATR, it did not 
reverse the ATR-associated decrease in CD4+ T cell proliferation (Figure 21). With 
30µM ATR treatment 76.2% of cells that did not divide (Figure 21B). This was 
comparable to the 1µM G-36 + 30µM ATR, 500nM G-36 + 30µM ATR, and 10nM G-36 
+ 30µM ATR treatments (Figure 21A). Treatment with ATR and lower levels of G-36 
actually increased the amount of undivided cells, although the increase was not 
significant. Treatment with 1μM G-36 only did not affect CD4+ T cell proliferation 
showing that blocking GPER-1 is not detrimental to CD4+ T cell proliferation (Figure 
21C). 
 
 
47 
 
Figure 21: The GPER-1 agonist, G-36, does not alter the effects of ATR on CD4
+
 T cells. Cells were 
gated on CD4
+
 V3
+
 T cells. AD10 splenocytes were cultured with 1µM G-36 + 30µM ATR (blue), 500nM 
G-36 + 30µM ATR (red), 100nM G-36 + 30µM ATR (green), 1µM G-36 only (pink), 30µM ATR (orange), 
30µM ATR + DMSO (brown), EtOH (shaded grey), DMSO (shaded cyan), or EtOH + DMSO (light purple). 
A. Cells were stained with CTV to monitor proliferation. Treatment with G-36 + ATR did not alleviate the 
ATR phenotype (Part B). C. Treatment with 1µM G-36 alone had no adverse effects on CD4
+
 T cells. 
Table shows MFI and percentage of undivided cells. Region markers indicate undivided cells. Percent 
undivided indicates cells that have not divided or have divided only a few times. Data representative of 3 
separate experiments. 
Treatment with ATR and G-36 did not alleviate the ATR-mediated reduction in 
the activation status of the T cells or reduce the frequency of Foxp3+ T cells (Figures 22 
and 23). Comparing the frequencies of CD25+ T cells in the 30μM ATR and G-36 
cultures to the 30µM ATR control (76.6% CD25+) shows that there is no significant 
difference between the atrazine treatment and the atrazine + G-36 treatments. Cultures 
containing 30μM ATR or 30μM ATR and G-36 had about a 1.9 fold decrease in the MFI 
of CD25 and about a 1.2 fold decrease in the frequencies of CD25+ T cells. The addition 
of DMSO into ATR treated cultures had no adverse effects on T cell activation as seen 
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by the 30μM ATR and DMSO control. Treatment with 1μM G-36 alone did not affect the 
activation status of CD4+ T cells showing that blocking GPER-1 is not detrimental to 
CD4+ T cell activation. These results show that antagonizing GPER-1 does not 
significantly alter CD4+ T cell activation in ATR treated cultures.  
Treatment with G-36 did not significantly decrease or increase the frequency of 
Foxp3+ CD4+ T cells compared to the 30µM ATR culture (Figure 23). 30μM ATR 
increased the frequency of Foxp3+ Tregs by 9.6 fold. The DMSO and EtOH + DMSO 
controls contained higher frequencies of Foxp3+ T cells compared to the ethanol control. 
It is unclear why the increase of Foxp3+ T cells is higher in DMSO containing cultures, 
but 30μM ATR and 500nM G-36 still increased the frequency of Foxp3+ T cells by 1.8 
fold compared to the EtOH + DMSO control. In this case, the 30μM ATR and 500nM G-
36 and 30μM ATR and 100nM G-36 treatments increased the frequency of Foxp3+ T 
cells more than 30μM ATR alone, although the difference is negligible. It is also 
interesting to note that T cell recovery was lower in the 30μM ATR and 30μM ATR + G-
36 cultures (data not shown). Since 30µM ATR is a potent PDE inhibitor, which can 
result in increased frequencies of Foxp3+ T cells (Figures 5 and 10), blocking GPER-1 
may not be potent enough to reverse the ATR effect. Signaling through GPER-1 can 
moderately inhibit CD4+ T cell proliferation and activation, but we cannot confidently say 
that GPER-1 is involved in the ATR-mediated phenotype since we did not see any 
alleviation of the ATR phenotype upon antagonizing the receptor. 
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Figure 22: The GPER-1 agonist, G-36, does not increase CD25 expression in ATR treated cultures. 
Cells were gated on CD4
+
 V3
+
 T cells. AD10 splenocytes were cultured with 1µM G-36 + 30µM ATR 
(blue), 500nM G-36 + 30µM ATR (red), 100nM G-36 + 30µM ATR (green), 1µM G-36 only (pink), 30µM 
ATR (orange), 30µM ATR + DMSO (brown), EtOH (shaded grey), DMSO (shaded cyan), or EtOH + 
DMSO (light purple). A. Treatment with G-36 + ATR had no effect on CD25 expression compared to the 
30µM ATR culture (Part B). C. Treatment with 1µM G-36 alone had no adverse effects on CD4
+
 T cells. 
Table shows MFI and percentage of CD25
+
 cells. Region markers indicate CD25
+
 cells. Data 
representative of 3 separate experiments. 
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Figure 23: The GPER-1 agonist, G-36, does not affect Foxp3 expression in ATR treated cultures. 
Cells were gated on CD4
+ 
V3
+
 T cells. AD10 splenocytes were cultured with 1µM G-36 + 30µM ATR 
(blue), 500nM G-36 + 30µM ATR (red), 100nM G-36 + 30µM ATR (green), 1µM G-36 only (pink), 30µM 
ATR (orange), 30µM ATR + DMSO (brown), EtOH (shaded grey), DMSO (shaded cyan), or EtOH + 
DMSO (light purple). A. Treatment with G-36 + ATR had no effect on Foxp3 expression compared to the 
30µM ATR culture (Part B). C. Treatment with 1µM G-36 alone did not affect Foxp3 expression. Table 
shows MFI and percentage of Foxp3
+
 cells. Region markers indicate Foxp3
+
 cells. Data representative of 
3 separate experiments. 
The aromatase inhibitor, YM511, does not alleviate the ATR 
phenotype 
Since ATR is known to induce expression of aromatase and subsequently 
increase levels of estrogen, we cultured cells in 30µM ATR and the aromatase inhibitor 
YM511. The hypothesis was that inhibition of aromatase would prevent any estrogen 
elevation, which would reduce the ATR effect if estrogen was playing a role in the ATR 
phenotype. As seen in Figure 25, the addition of 30µM ATR + 5nM YM511 had no 
significant effect on CD4
+
 T cell proliferation (65.6% of undivided cells) versus 30µM 
ATR alone (61.5% of undivided cells). Treatment with 0.5nM and 1nM YM511 in ATR 
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cultures slightly decreased the percentage of undivided cells more than the 0.1nM and 
5nM YM511 treated cultures suggesting that the aromatase inhibitor could follow a non-
monotonic dose response (14). Treatment with 5nM YM511 alone did not affect CD4+ T 
cell proliferation showing that it does not interfere with CD4+ T cell expansion. 
As seen in Figure 25A, addition of 5nM YM511 into ATR treated cultures did not 
increase the percentage of CD25+ T cells compared to the 30µM ATR culture (Figure 
25B). Treatment with 0.1nM YM511 in ATR cultures decreased the frequency of CD25+ 
T cells more than the 30μM ATR control but the difference was not significant. The 
addition of YM511 alone did not affect the frequency of CD25+ T cells showing that it 
does not interfere with CD4+ T cell activation. These results suggest that aromatase 
induction may not be involved in the ATR-mediated phenotypes, although further tests 
need to be done to test YM511 aromatase inhibitor activity.  
 
Figure 24: Inhibiting aromatase does not alleviate the proliferation inhibition caused by ATR 
exposure. Cells were stimulated with plate bound anti-CD3 and anti-CD28 antibodies and gated on 
CD4
+
 T cells. B10.BR splenocytes were cultured with 30µM ATR + 5nM YM511 (cyan), 30µM ATR + 1nM 
YM511 (green), 30µM ATR + 0.5nM YM511 (pink), 30µM ATR + 0.1nM YM511 (blue), 30µM ATR 
(orange), 5nM YM511 only (red), 7.5uL EtOH (shaded light purple), or 5uL EtOH (shaded grey). Cells 
were stained with CTV to monitor proliferation (top panels). Table shows MFI and percentage of 
undivided cells. Region markers indicate undivided cells. Percent undivided indicates cells that have not 
divided or have divided only a few times. Data representative of 2 separate experiments. 
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Figure 25: Inhibiting aromatase does not alleviate the inhibition of activation caused by ATR 
exposure. Cells were stimulated with plate bound anti-CD3 and anti-CD28 antibodies and gated on 
CD4
+
 T cells. B10.BR splenocytes were cultured with 30µM ATR + 5nM YM511 (cyan), 30µM ATR + 1nM 
YM511 (green), 30µM ATR + 0.5nM YM511 (pink), 30µM ATR + 0.1nM YM511 (blue), 30µM ATR 
(orange), 5nM YM511 only (red), 7.5uL EtOH (shaded light purple), or 5uL EtOH (shaded grey). CD25 
expression was not affected compared to the 30µM ATR culture. Treatment with 5nM YM511 has no 
adverse effect on CD4
+
 T cell activation (Part B). Table shows MFI and percentage of CD25
+
 cells. 
Region markers indicate CD25
+
 cells. Data representative of 2 separate experiments. 
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Discussion 
 
ATR is the most common drinking water contaminant in the United States and it 
has been linked to adverse human health effects and environmental effects, such as 
increases in cancer (28, 29) and feminization of amphibians (34). However, the potential 
effects of ATR on adaptive immunity are not well understood. Our previous studies 
showed that ATR exposure decreased CD4+ T cell proliferation (Figure 4) and activation 
(Figure 6). It was also shown to increase the frequency of Foxp3+ Tregs (Figure 5). ATR 
is a PDE inhibitor, but the decreased activation status of the CD4+ T cells was not 
completely mimicked by pharmacologically increased cAMP (Figure 6). In addition, a 
sex bias upon treatment with ATR emerged (Figure 7) with male-derived cells being 
more adversely affected. These latter results suggested that, as an endocrine disrupting 
compound, ATR may be increasing estrogen levels in vitro and causing a more severe 
phenotype than that seen with PDE inhibition alone. Our focus turned to the G-protein 
coupled estrogen receptor, GPER-1 because it has demonstrated immunosuppressive 
effects in experimental autoimmune encephalomyelitis (EAE, mouse model of multiple 
sclerosis) (66) and can increase cAMP (63). This led us to examine the role of estrogen 
and GPER-1 signaling in ATR-mediated effects of decreased CD4+ T cell activation, 
proliferation and increase in the frequency of Foxp3+ CD4+ T cells.  
We began these studies by extending the previous results showing that ATR 
exposure decreased CD4+ T cell proliferation and activation (Figure 6) and increased 
the frequency of Foxp3+ Tregs (Figure 5). We found that CD4
+ T cells activated in the 
presence of atrazine had a decrease in the expected CD62L down-regulation (Figure 7) 
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and decreased PD-1 expression (Figure 8). This phenotype correlates with decreased 
activation because CD62L is highly expressed on naïve cells and decreases upon 
activation (79), while PD-1 expression increases upon activation and has been shown to 
increase in the presence of estrogen (80). The effects on CD62L expression were 
concentration dependent (Figure 8), confirming that ATR treatment prevents T cell 
activation and that higher concentrations are more toxic.  
Our previous results have shown that treatment with the phosphodiesterase 
inhibitor Pentoxyfilline inhibited T cell proliferation (Figure 4) and activation (Figure 6), 
but was not as potent as 30μM ATR. Here, we examined the effect of PTX treatment on 
Foxp3 expression. PTX increased the frequency of Foxp3+ T cells by 2 fold (Figure 10). 
This is similar to the effects of 30μM ATR, which increases the frequency of Foxp3+ T 
cells by 2-5 fold. This suggests that a significant elevation of intracellular cAMP is 
sufficient to stabilize Foxp3 expression. It also suggests that the PDE inhibitory activity 
of ATR is sufficient for the increase in the frequency of Foxp3+ Tregs. In contrast, the 
inhibition of T cell proliferation and activation by PTX did not completely mimic the 
effects of ATR suggesting that elevated cAMP alone is not sufficient to decrease 
activation in this system and is consistent with the hypothesis that ATR is functioning via 
elevated estrogen levels. 
 To explore the possible effects of estrogen in the ATR-mediated decrease in 
proliferation, activation and increase in Foxp3+ T cells, primary splenocytes were 
cultured in the presence of estrogen. In our experiments, addition of exogenous 
estrogen (17β-estradiol) inhibited T cell activation and proliferation following a non-
monotonic dose response. Non-monotonic dose responses are exhibited by endocrine 
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hormones and endocrine disrupting compounds and display a non-linear relationship 
between dose and effect (14). Estrogen at 5ng/ml inhibited CD4+ T cell proliferation and 
CD25 expression slightly more than 10ng/ml of estrogen, but 25ng/ml was more 
suppressive than 5ng/ml (Figure 12). These results are consistent with non-monotonic 
dose response curves for endocrine disruptors. Endocrine disrupting compounds, like 
estrogen, often display effects at low doses and follow non-monotonic dose response 
curves (36). Since estrogen can interact with multiple estrogen receptors, it is also 
possible that estrogen can bind different estrogen receptors and subsequently exert 
differential effects on target cells. Because the mice we used are wild type and express 
multiple estrogen receptors, these results cannot distinguish whether the estrogen effect 
is due to triggering of ER, ER, and/or GPER-1.  
When cells were cultured with both ATR and estrogen, the estrogen and ATR 
synergized to further decrease activation and proliferation more than ATR or estrogen 
alone (Figures 12 and 13). This unexpected result raises the possibility that ATR may 
not significantly elevate estrogen levels in vitro because we would expect the increased 
estrogen to decrease CD4+ T cell activation and proliferation more than what has been 
observed with 30µM ATR treated CD4+ T cells. Experiments to determine the estrogen 
concentrations in the various cultures have failed due to technical difficulties.   
As mentioned above, there are multiple estrogen receptors that may be 
responsible for the observed estrogen effects. To determine which are playing a central 
role in the estrogen and ATR phenotype, we began by testing whether ER stimulation 
could mimic the inhibitory effects seen with ATR treatment. Cells were exposed to the 
ERα agonist PPT during a 4 day activation culture. As seen in Figure 14, PPT did not 
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decrease proliferation or activation of CD4+ T cells. It also did not increase the 
frequency of Foxp3+ T cells. These results suggest that stimulation of ERα is not playing 
an important role in the ATR-mediated effects. 
A second estrogen receptor that may be mediating the ATR effect is GPER-1. 
Previously published studies have shown that treatment with the GPER-1 specific 
agonist, G-1, is capable of decreasing the disease severity of experimental autoimmune 
encephalomyelitis (EAE, a mouse model of multiple sclerosis) by inducing Tregs and 
increasing the production of anti-inflammatory cytokines (66). Another factor favoring 
the idea of GPER-1 involvement in the ATR–mediated phenotype is that GPER-1 
stimulation leads to an increase in cAMP (63). However, elevated concentrations of 
PTX do not fully mimic the ATR effects (Thueson, et al. in revision).  
Signaling through GPER-1 via the agonist G-1 causes a moderate decrease in 
proliferation and activation although not a consistent increase in Foxp3 (Figures 15, 16, 
and 17). This is the first set of experiments showing that treatment with G-1 negatively 
impacts the in vitro CD4+ T cell response. If G-1 triggering of GPER-1 worked as 
predicted, we would expect a significant decrease in CD25 expression and decreased 
frequency of Foxp3+ CD4+ Tregs. However, the only phenotype observed was a 
significant decrease of CD4+ T cell proliferation. Treatment with G-1 in vitro appears to 
negatively impact proliferation of CD4+ effector T cells. It has recently been shown that 
G-1 may bind a variant of ERα called estrogen receptor alpha-36 (ER-α36)(88, 89). This 
makes our interpretations of the G-1 data more difficult. 
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One interesting discovery was that Tregs in the presence of ATR, PTX and the 
GPER-1 agonist G-1 did not proliferate as well as Tregs treated with vehicle controls. In 
EtOH controls, Tregs proliferated similar to the CD4
+ effector T cells. Tregs in the presence 
of PTX, ATR or G-1 proliferated more than the CD4+ T effector cells, but not nearly as 
well as the Tregs in the ethanol and DMSO  vehicle-control cultures (Figures 11 and 18). 
The inhibition of proliferation of effector CD4+ T cells was consistent with the observed 
increase in the Treg population. It is in the nature of regulatory T cells to suppress an 
immune response, but it is unclear what is altering the proliferation status of the Tregs in 
vitro. It is known that increased levels of cAMP can inhibit effector lymphocyte 
proliferation (81), but Tregs naturally harbor increased levels of intracellular cAMP and 
even use this to suppress conventional T cells (82). Thus Tregs may not be as sensitive 
as CD4+ T effector cells to increased cAMP levels. This would allow Tregs to proliferate 
better than effector T cells in conditions where there is an increase in cAMP. Since 
CD4+ effector T cells don’t normally have high levels of cAMP, they may be more 
sensitive to cAMP increases which, in turn, may prevent effector T cell proliferation. This 
could explain why we saw almost complete inhibition of CD4+ effector T cell proliferation 
and minimal inhibition of Treg proliferation. This effect could also be mediated through 
antigen presenting cells, such as dendritic cells (DCs) (83), although previous studies 
have shown that DC phenotypes were not altered in these ATR treated cultures (data 
not shown). 
Since we saw a decrease in the overall number of CD4+ T cells in culture upon 
treatment with ATR, PTX, and G-1 (data not shown), the increased frequency of Foxp3 
expression may be due to a combination of natural Treg (nTreg) proliferation and the 
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conversion of CD4+ effector T cells into Tregs (iTregs). The nTreg proliferation in ATR 
cultures was not as robust as that seen in ethanol cultures yet there was still an 
increased frequency of Foxp3+ T cells upon treatment with ATR. The ATR-associated 
increase in Foxp3+ T cell frequency may be due to the appearance of iTregs, which could 
be mediated through the increase in cAMP levels (18). The results from Figures 11 and 
18 suggest that expansion of nTregs and induction of iTregs may be occurring in ATR 
treated cultures. In the presence of ATR, Tregs proliferated more than the CD4
+ effector 
T cells showing that the natural Treg population was expanding. However, this 
expansion was not comparable to the proliferation of Tregs in the EtOH vehicle control 
(Figure 11), where the proliferation of Tregs was similar to the proliferation of CD4
+ 
effector T cells. The slight inhibition of Treg proliferation and increase in overall frequency 
of Foxp3+ T cells in ATR treated cultures may indicate that conversion of CD4+ effector 
T cells into Foxp3+ Tregs is occurring. 
In order to further investigate the effects of GPER-1 signaling in ATR-mediated 
effects, we antagonized GPER-1. If GPER-1 signaling was involved, then antagonizing 
GPER-1 should alleviate the ATR-mediated effects. Initial attempts to antagonize 
GPER-1 with G-15 were difficult as G-15 has off-target effects due to its ability to 
stimulate ERα and ERβ (77). Non-specific binding of G-15 to other estrogen receptors 
may explain why treatment with 15μM ATR and G-15 increased the severity of the ATR-
mediated effects (Figure 19). There have been many studies using G-15 where they 
conclude that it can effectively block GPER-1 stimulation, but our results suggest 
otherwise. Treatment with 15μM ATR and G-15 further decreased CD4+ T cell 
proliferation (Figure 19) and activation (Figure 20) compared to the 15μM ATR control. 
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Since G-15 can bind other estrogen receptors, we further explored antagonizing GPER-
1 with the more selective antagonist, G-36 (77). G-36 is similar to G-15, but it has an 
additional functional group that prevents it from interacting with ER and ER (77). 
Antagonizing GPER-1 with G-36 did not modulate ATR effects on CD4+ T cell 
proliferation or activation, or alter the frequency of Foxp3+ T cells (Figures 21, 22, and 
23). If G-36 had worked as predicted, significant increases in the frequency of 
proliferating and activated CD4+ T cells should have been observed, as well as no 
increase in the Foxp3+ frequency. Thus, our results appear to support the conclusion 
that GPER-1 signaling is likely not involved in ATR-mediated effects on CD4+ T cells. 
ATR elevates estrogen by stimulating the expression of the aromatase II gene.  
In order to assess whether ATR-induction of aromatase was mediating an effect on 
CD4+ T cells by elevating estrogen levels, cells were stimulated in the presence of ATR 
with or without the aromatase inhibitor YM511. According to our hypothesis, if 
aromatase induction was inhibited there would be significantly lower levels of estrogen 
present in the ATR cultures and there would be increased CD4+ T cell proliferation and 
activation and a decrease in the frequency of Foxp3+ T cells. As seen in Figures 24 and 
25, the presence of the aromatase inhibitor did not decrease the severity of ATR. CD4+ 
T cells still exhibited decreased proliferation and decreased expression of CD25. This 
suggests that ATR may not be inducing aromatase or that induction of aromatase has 
no effect on CD4+ T cells. Before coming to a conclusion, the functionality of the 
aromatase inhibitor in this system needs to be confirmed.  
In summary, here we show that ER stimulation does not inhibit CD4
+
 T cell 
proliferation or activation and does not increase the frequency of Foxp3+ T cells. While 
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ER had no effect, GPER-1 signaling with G-1 inhibited CD4+ T cell proliferation, but did 
not significantly reduce the frequency of activated CD4+ T cells or consistently increase 
the frequency of Foxp3+ T cells in vitro. Blocking GPER-1 with the antagonist G-15 
potentiated the ATR phenotype while antagonizing GPER-1 with G-36 did not 
significantly alleviate the ATR-mediated effects on CD4+ T cells. Treatment with the 
aromatase inhibitor YM511 also did not alleviate the ATR-mediated effects on CD4+ T 
cells. Overall, the results presented in this thesis suggest that ATR may not be working 
to inhibit CD4+ T cells through increasing estrogen levels in vitro.  Further, elevated 
estrogen levels and GPER-1 signaling does not appear to be involved in the ATR-
mediated decrease in CD4+ T cell activation and proliferation and increase in frequency 
of Foxp3+ T cells. 
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Future Directions 
In order to further the understanding of estrogen-mediated effects in ATR treated 
cultures, it would be beneficial to examine a few more parameters in future experiments. 
In order to assess whether ATR is increasing the levels of estrogen in vitro, an estrogen 
enzyme-linked immunosorbent assay (ELISA) should be used to analyze estrogen 
concentrations in ATR and ethanol cultures. We have saved serum samples from ATR 
and ethanol treated cultures to determine the levels of estrogen present in each culture 
on day 4. We have recently purchased an estrogen ELISA and will analyze serum 
samples as soon as the kit arrives. This piece of data will strongly determine if elevated 
estrogen levels are mediating the observed effects on our CD4+ T cells in ATR treated 
cultures. 
Even if ATR is not elevating estrogen in vitro, it is possible that estrogen 
signaling is still playing a role in the ATR mediated decrease in CD4+ T cell activation 
and proliferation and increase in the frequency of Foxp3+ Tregs. The involvement of 
GPER-1 still remains promising because stimulation with G-1 displayed similar results 
on CD4+ T cells as did ATR treatment. It has also been shown that ATR can weakly 
interact with GPER-1 (67) showing that even if there is no increase in estrogen levels, 
GPER-1 stimulation could still be occurring. The fact that lower concentrations of ATR 
have proven to be more potent than higher concentrations of ATR in animal models (36) 
suggests that ATR may only need to cause weak interactions in order to mediate 
adverse health effects.  
 
 
62 
Since antagonizing GPER-1 has proven to be difficult, more definitive 
conclusions could be drawn if we were able to use GPER-1 knockout mice. If GPER-1 
mice are not available, it would be possible to use siRNA to knock down GPER-1 
expression. If treatment of these cells (cells derived from GPER-1 knockout mice or 
cells whose GPER-1 expression is inhibited) with 30μM ATR does not affect 
proliferation or activation as severely as wild type mice, then it would suggest that 
GPER-1 stimulation is involved. 
If it turns out that ATR is increasing the level of estrogen in our in vitro cultures, it 
is possible that there is synergy between the classical estrogen receptors and GPER-1. 
ER/ER stimulation along with GPER-1 stimulation have been shown to stimulate 
proliferation of mouse Sertoli (testicular) cells (84) and decrease testosterone 
production (85). The increased levels of estrogen could be binding ER/ER and 
GPER-1 causing the increased inhibition on proliferation and activation. In order to test 
if ER and GPER-1 stimulation synergize, we would need to culture cells in the 
presence of PPT and G-1. The effects of ER alone and in conjunction with GPER-1 
still need to be assessed. It would be beneficial to culture cells in the presence of ATR 
and PPT or ATR and G-1 in order to see if we can mimic the increased severity seen in 
ATR treated cultures supplemented with estrogen. It would also be possible to test 
these effects in ER and ER knockout mice. The expression levels of ERα/ERβ and 
GPER-1 on ATR treated CD4+ T cells still need to be assessed. 
Since ATR has been shown to disrupt multiple tissues, the in vivo effects of ATR 
should also be assessed. ATR is found in many tissues throughout the body and can 
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elicit different effects within the body than it can in vitro (13). One of the main differences 
is that ATR can increase hormone release from the hypothalamic-pituitary-adrenal axis 
which may significantly alter hormone concentrations compared to in vitro cultures (86). 
We may also get additional differences in sex hormone levels since ATR can affect 
reproductive tissues/organs (34). The effects of ATR during an active immune response 
(challenge with antigen in vivo) would also be interesting to examine since our data 
indicates differences in CD4+ T cell activation and proliferation and changes in the 
frequency of Foxp3+ T cells. After we are able to fully characterize the effects of ATR in 
vivo and in vitro, the next step would be to examine the effects of major metabolites, like 
DACT (13), on CD4+ T cells. 
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